{"pii": "S2211124722005836", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "attachments", "$$": [{"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2211124722005836-fx1.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2211124722005836/fx1/DOWNSAMPLED/image/jpeg/7583ac6b88638f1c063aa830b6c0251a/fx1.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "39459"}, {"#name": "pixel-height", "_": "375"}, {"#name": "pixel-width", "_": "375"}, {"#name": "attachment-type", "_": "IMAGE-DOWNSAMPLED"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2211124722005836-fx1.sml"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2211124722005836/fx1/THUMBNAIL/image/gif/44a08d6e894815d28c9542959a4c3f32/fx1.sml"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.sml"}, {"#name": "extension", "_": "sml"}, {"#name": "filesize", "_": "10321"}, {"#name": "pixel-height", "_": "164"}, {"#name": "pixel-width", "_": "164"}, {"#name": "attachment-type", "_": "IMAGE-THUMBNAIL"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2211124722005836-fx1_lrg.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2211124722005836/HIGHRES/image/jpeg/fbb5c336e056b9623a40d4ef91080e61/fx1_lrg.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1_lrg.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "173454"}, {"#name": "pixel-height", "_": "996"}, {"#name": "pixel-width", "_": "996"}, {"#name": "attachment-type", "_": "IMAGE-HIGH-RES"}]}]}, {"#name": "abstract", "$": {"id": "abs0010", "view": "all", "class": "author"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0010"}, "_": "Summary"}, {"#name": "abstract-sec", "$": {"id": "abssec0010", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0010", "view": "all"}, "_": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants."}]}]}, {"#name": "abstract", "$": {"class": "graphical", "id": "abs0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0015"}, "_": "Graphical abstract"}, {"#name": "abstract-sec", "$": {"id": "abssec0015", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0015", "view": "all"}, "$$": [{"#name": "display", "$$": [{"#name": "figure", "$": {"id": "undfig1"}, "$$": [{"#name": "link", "$": {"xmlns:xlink": true, "locator": "fx1", "type": "simple", "href": "pii:S2211124722005836/fx1", "id": "aep-link-id4"}}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "author-highlights", "id": "abs0020", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0020"}, "_": "Highlights"}, {"#name": "abstract-sec", "$": {"id": "abssec0020", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0020", "view": "all"}, "$$": [{"#name": "list", "$": {"id": "ulist0010"}, "$$": [{"#name": "list-item", "$": {"id": "u0010"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0010", "view": "all"}, "_": "LY-CoV1404 potently neutralizes SARS-CoV-2 Omicron, BA.2 Omicron, and Delta variants"}]}, {"#name": "list-item", "$": {"id": "u0015"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0015", "view": "all"}, "_": "No loss of potency against currently circulating variants"}]}, {"#name": "list-item", "$": {"id": "u0020"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0020", "view": "all"}, "_": "Binding epitope on RBD of SARS-CoV-2 is rarely mutated based on current GISAID data"}]}, {"#name": "list-item", "$": {"id": "u0025"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0025", "view": "all"}, "_": "Breadth of neutralizing activity and potency supports clinical development"}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "teaser", "id": "abs0025", "view": "all"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0025", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0025", "view": "all"}, "_": "Westendorf et\u00a0al. show that LY-CoV1404 is a potent SARS-CoV-2-binding antibody that neutralizes all known variants of concern and that its epitope is rarely mutated."}]}]}]}}